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Measurement of the Bovine Pancreatic Trypsin Inhibitors 
by Radioimmunoassay * 
E . F I N K * * and L . J . G R E E N E 
Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA 
Bovine pancreas contains two polypeptide trypsin inhibitors which are not 
homologous and differ in their inhibitory activity towards chymotrypsin, kalli-
krein, elastase and other serine proteinases [1] . The Kunitz inhibitor [2 ,3] and 
the Kazal inhibitor [4, 5] are present in approximately equimolar concentrations 
in bovine pancreatic tissue [6] , yet only the Kazal inhibitor is detectable in the 
pancreatic juice [6 ,7 ] . The Kazal inhibitor has been named the pancreatic secre-
tory trypsin inhibitor, PSTI [8] because its concentration in the pancreatic juice 
parallels that of the exocrine secretory proteins [7, 9, 10]. The Kunitz inhibitor is 
considered the "intracellular" inhibitor [7] . However, no direct information is 
available concerning the intracellular localization of these inhibitors in the pan-
creas. A sensitive and specific analytical method for the measurement of Kazal 
and Kunitz inhibitors at the picogram-nanogram level is required for intracellular 
distribution studies. The preparation of trace labelled mI-Kunitz inhibitor by the 
chloramine T method and its use in a radioimmunoassay have been described by 
A R N D T S et a l . [11]. In this communication we report the preparation of l 2 i 
derivatives of Kazal and Kunitz inhibitors by the lactoperoxidase method and 
present a radioimmunoassay for each inhibitor. 
Radioiodination 
The Kazal and Kunitz trypsin inhibitors were iodinated with carrier free Na12T 
by lactoperoxidase in the presence of hydrogen peroxide [12, 13]. The experi-
mental conditions for iodination and purification were identical for both inhibi-
tors. The results obtained for the Kunitz inhibitor were essentially the same as 
those illustrated for the Kazal inhibitor in Figs. 1 and 2. Kazal inhibitor was 
prepared from bovine pancreas [8] and the Kunitz inhibitor, isolated from bovine 
lung was supplied by Bayer AG. 
Inhibitor,4 jig, was iodinated by incubation with 1 mCi Na 1 2 5I(IMS 30, Amer-
sham) and 1 pg lactoperoxidase (Calbiochem) in 30 pi of 0.13 M potassium phos-
* Research carried out at Brookhaven National Laboratory under the auspices of the 
U.S. Atomic Energy Commission. 
** Visiting Biochemist at Brookhaven National Laboratory, 1972-1974. Supported by 
Deutsche Forschungsgemeinschaft. On leave from Institut für Klinische Chemie und Kli-
nische Biochemie der Universität München. 
1 The trypsin inhibitor from bovine lung, kallikrein inactivator, is identical in amino acid 
sequence and disulfide pairings to the Kunitz inhibitor [14]. 
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Fig. 1. Isolation of l2*I Kazal inhibitor by gel filtration on Sephadex G-50F. The iodination 
reaction mixture was applied to a Sephadex G-50F column, 0.6 x 120 cm, equilibrated with 
0.05 M Tris-HCl buffer, pH 8.6, containing 0.5% bovine serum albumin, 0.5 M KCl and 
0.02% NaNj. The column was developed at 3 ml/h at 4 
Fig. 2. SDS-polyacrylamide gel electrophoresis of iodinated Kazal inhibitor. Electrophoresis 
was carried out for 15 h, 2 1 , 9 volts cm in Tris-glycine buffer, pH 8.3, 20% acrylamide, 
containing 0.1% sodium dodecyl sulfate. The samples were treated with 1% /?-mercaptoe-
thanol and 1% sodium dodecyl sulfate in Tris-HCl buffer, pH 6.8, at 100: for 2 min before 
electrophoresis [16]. Electrophoretic migration was from top (cathode) to bottom (anode). 
The samples are identified by the fraction numbers from the Sephadex G-50 elution diagram 
given in Fig. 1. Effluent corresponding to fractions 29, 30 + 31, and 32 were examined at two 
loading concentrations. Unlabelled Kazal inhibitor was also added to fraction 29. The electro-
phoretogram was dried and stained with coomassie blue before autoradiography 
phate buffer, pH 6.1, at 21 C. Hydrogen peroxide, 2 pi of a 0.1 mg/ml solution, 
was added five times at 30 min intervals [15]. After 2.5 hours the reaction was 
stopped by the addition of 20 pi of 0.3% NaN3, 200 pi of 0.1% Nal and 600 pi of 
0.05 M Tris-HCl buffer, pH 8.6, containing 0.5% bovine serum albumin (Frac-
tion V, Miles Laboratories), 0.5 M KCl and 0.02% NaN3. The solution was imme-
diately subjected to gel filtration on Sephadex G-50 (Fig. 1). 
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Fig. 3. Interaction of 12:>I Kunitz inhibitor with bovine trypsin demonstrated by gel filtration. 
The Sephadex G-50 column was the same as described in the legend to Fig. 1. Top panel : ,25I 
Kunitz inhibitor. Middle panel: ,25I Kunitz, inhibitor incubated with 0.5 mole equivalents of 
bovine trypsin for 20 min at pH 8.0, 21 : . Bottom panel: 125I Kunitz inhibitor incubated with 
1.5 mole equivalents of bovine trypsin for 20 min at pH 8.0,21 
The major iodinated product, accounting for 64% of the recovered radioactiv-
ity is eluted as a symmetrical peak in fractions 27-33, the same volume in which 
unlabelled inhibitor is eluted. The gel filtration step effectively separated the iodi-
nated inhibitor from small amounts of high molecular weight iodinated material 
(fractions 16-25) presumably derived from the lactoperoxidase preparation and 
from low molecular weight radioactive material eluted in fractions 41^46, which is 
probably free 125I. 
The effluent from the Sephadex G-50 column was examined by SDS-polyacryl-
amide gel electrophoresis [16] in order to determine the molecular weight of the 
125I labelled material. The autoradiogram presented in Fig. 2 shows that the major 
iodinated product obtained from Kazal's inhibitor (Fig. 1, fractions 29-32) con-
tains a single, iodinated component after reduction with ß-mercaptoethanol. The 
electrophoretic mobility of the reduced iodinated material was the same as that of 
reduced unlabelled Kazal inhibitor, indicating that no peptide bond cleavage had 
occurred during the iodination procedure or during isolation of the product. The 
iodinated material in fractions 18 and 23 appears to be of higher molecular weight 
than the inhibitor, which is consistent with their elution properties from Sephadex 
G-50. The behavior of the Kunitz inhibitor was essentially the same as the Kazal 
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inhibitor for iodination, gel filtration, and SDS-polyacrylamide gel electropho-
resis. 
The Kazal and Kunitz inhibitors prepared in this manner contain ^0.5-0.8 
moles I25I per mole peptide (~ 180mCi/mg). This value may be somewhat low 
because it was calculated on the basis of the amount of radioactivity incorporated 
into the inhibitor fraction isolated by gel filtration and on the assumption of 
100% recovery of inhibitor from the column. No attempt has been made to 
separate labelled and unlabelled forms of the inhibitors. 
125I labelled Kazal and Kunitz inhibitors form a complex with bovine trypsin. 
Figure 3 illustrates the results of a gel filtration experiment with 125I Kunitz 
inhibitor. The top panel gives the elution diagram of the inhibitor. The middle 
and bottom panels show the results obtained when inhibitor was preincubated 
with 0.5 and 1.5 mole equivalents of trypsin, respectively. When the inhibitor is 
present in excess relative to trypsin, two radioactive peaks are demonstrable 
(middle panel). They correspond to free inhibitor (fractions 27-33) and inhibitor-
trypsin complex (fractions 18-22). More than 98% of the radioactive inhibitor is 
eluted in the inhibitor-trypsin complex region when trypsin is in excess (bottom 
panel). 
Iodinated preparations of Kunitz and Kazal inhibitor were stored at 4 in the 
Sephadex G-50 elution buffer. They were generally rechromatographed on Se-
phadex G-50 after 2-3 weeks storage prior to use for radioimmunoassay. Upon 
rechromatography most of the iodinated material was eluted in the position of the 
inhibitor, with 10-15% of the radioactivity in the low molecular weight region 
(fractions 44^49, Fig. 1). 
Radioimmunoassay Procedure 
Antiserum to Kunitz inhibitor was prepared from rabbits immunized with the 
antigen in incomplete Freund's adjuvant.Theimmunoglobulin fraction was isolated 
by ammonium sulfate precipitation and treatment with DEAE-Sephadex. Anti-
serum to Kazal inhibitor was prepared from rabbits with Kazal inhibitor coupled 
to human albumin and used without further purification. The double antibody 
method was employed for the radioimmunoassay using goat antirabbit IgG 
serum (Miles Laboratories) as the second antibody to separate bound inhibitor 
from free inhibitor [17]. 
The titration curves for the Kazal and Kunitz inhibitors are given in Fig.4. 
The abscissa on the top of the figure gives the dilutions of the rabbit antiserum for 
the Kazal inhibitor and the abscissa on the bottom gives the dilution for the anti-
Kunitz IgG. These data show that 85-90% of the radioactivity in each l 2 ì inhibi-
tor preparation is bound by the antibody. 
Standard curves for the radioimmunoassays of Kazal and Kunitz inhibitors 
are given in Figs. 5 and 6, respectively. The data are presented as a logit-log plot to 
linearize the dose response relationship [18, 19]. 7, the percent 125I inhibitor 
bound, is expressed as B — N/B0—N x 100; ß, the amount bound; ßo, the amount 
bound in the absence of unlabelled inhibitor; and N, the amount bound in the 
absence of antibody to the inhibitor. The Kazal inhibitor can be accurately as-
sayed in the range of 50 to 2500 picograms per determination with deviations of 
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Fig.4. Antiserum titration curves for l25I Kazal and 12*I Kunitz inhibitors. Each tube contain-
ing 100 ul 125I inhibitor (25000c min). 100 ul antiserum and 300 ul 0.05 M potassium phos-
phate buffer, pH 7.6, 0.25% bovine serum albumin and 0.02% NaN*, was held at 21 for 48 
hours. Bound inhibitor was separated by the addition of 100 ul goat antirabbit IgG serum 
(1:30) and 100 ul rabbit serum (1:600) followed by incubation for 24 hours at 21 . The 
amount of bound inhibitor was determined by counting the precipitate after centrifugation 
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Fig. 5. Standard curve for the radioimmunoassay of Kazal inhibitor. Each tube contained 
100 ul ,25I Kazal inhibitor (25000 cmin), 100 ul of antiserum at a dilution sufficient to bind 
50% of the 125I Kazal inhibitor in the absence of unlabelled inhibitor, 200 ul 0.05 M potassium 
phosphate buffer, pH 7.6. 0.25% bovine serum albumin and 0.25% NaN> and 100 ul unla-
belled Kazal inhibitor in the amounts given in the ordinate. The conditions for incubation and 
separation of bound antibody are given in the legend to Fig.4. The data are presented in the 
form of the logit-log plot [19] 
replicates ± 10% or less. The Kunitz inhibitor can be determined in the range of 
100 to 5000 picograms with the same precision. We have not attempted to in-
crease the sensitivity of the assay although it is probable that sensitivity could be 
increased by using higher specific activity iodinated inhibitors. Since the Kazal 
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Fig.6. Standard curve for the radioimmunoassay of Kunitz inhibitor. 125I Kunitz inhibitor 
and antibody to Kunitz inhibitor were employed using the same volumes of reagents and 
incubation conditions as given in the legend to Fig. 5 
and Kunitz inhibitors contain 2 and 4 moles tyrosine per mole peptide, the 
iodinated inhibitors used here, 0.5-0.8 moles 125I per mole peptide respectively, are 
undersubstituted. However, increasing the extent of iodination may interfere with 
binding to antibody and reduce the stability of the iodinated inhibitor. The sys-
tem described here is reasonably stable and provides high sensitivity. 
Validation of the Radioimmunoassays 
There is no detectable cross reactivity between the Kazal and Kunitz inhibi-
tor-antiserum systems. Iodinated Kazal inhibitor was not bound by antiserum to 
Kunitz inhibitor nor was iodinated Kunitz inhibitor bound by antiserum to 
Kazal inhibitor under the conditions of the double antibody radioimmunoassay. 
Ten to 50-fold molar excess of one inhibitor had no effect on the quantitative 
determination of the second inhibitor. 
Trypsin interfered with the assay of the Kunitz inhibitor and to a smaller 
extent with the assay of the Kazal inhibitor. This interference was reflected in a 
reduction of the amount of iodinated inhibitor bound to the antibody. This 
suggests that the inhibitor-trypsin complex is not as effectively bound to the 
antibody as is the inhibitor. For this reason, samples which may contain trypsin 
are treated with 2.5% trichloroacetic acid (TCA) to precipitate the trypsin while 
the inhibitors remain in solution [2 ,4] . The recovery of each iodinated inhibitor 
added to pancreatic juice or homogenates of pancreas was 70-80% after treat-
ment with TCA. 
The Kazal and Kunitz inhibitor content of TCA extracts of pancreatic tissue 
and juice determined by radioimmunoassay was independent of the dilution at 
which the samples were assayed, i.e. the values of Y (per cent radioactivity bound) 
for serial dilutions defined lines which were parallel to the standard curves given 
in Figs. 5 and 6. This parallelism in the dose-response relationship is a necessary, 
though not sufficient, criterion for the demonstration of identity between the 
immunoreactive material present in the tissue extract and the inhibitor 
standard [20]. Additional support for this identity comes from gel filtration expe-
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riments for the estimation of the molecular weight of the immunoreactive mate-
rial present in pancreas. The TCA-soluble immunoreactive Kazal- and Kunitz-
like materials from tissue were eluted from Sephadex G - 5 0 in the same volume as 
the inhibitor standards. These results validate the radioimmunoassay for both the 
antigen interaction with the antibody and the molecular weight of the antigen. 
These experiments do not preclude the possibility of the existence in tissue of 
larger, TCA-insoluble species related to Kazal and Kunitz inhibitors. 
The radioimmunoassays described here provide a method to measure pico-
gram quantities of both the Kazal and Kunitz inhibitors in tissue extracts and 
physiological fluids. The sensitivity and specificity of these assays now permit the 
examination of the synthesis, segregation and secretion of the pancreatic trypsin 
inhibitors at a level which hitherto had not been possible. 
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